FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
ConclusionsBoth FOLFIRINOX and G-nP are viable options for neoadjuvant treatment of PDA. In this study, neoadjuvant FOLFIRINOX was associated with a 4.9-month improvement in survival compared with G-nP after adjustment for covariates.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Borderline Tumor | Cancer & Oncology | CT Scan | Neoadjuvant Therapy | Pancreas | Study